공시 • Jun 03
OncoSec Medical Receives Notice from Nasdaq Regarding Minimum Bid Price Requirement On June 1, 2023, OncoSec Medical Incorporated (the Company") received notice (the Notice") from the Nasdaq Stock Market LLC (Nasdaq") that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), as the minimum bid price of the Company's common stock has been below $1.00 per share for 30 consecutive business days. The Notice has no immediate effect on the listing of the Company's common stock, which will continue to trade at this time on the Nasdaq Capital Market under the symbol ONCS." In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until November 28, 2023, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company's common stock must meet or exceed $1.00 per share for at least ten consecutive business days during this 180 calendar day period. In the event the Company does not regain compliance by November 28, 2023, the Company may be eligible for an additional 180 calendar day grace period if it meets the continued listing requirement for market value of publicly held shares ($1 million) and all other initial listing standards for the Nasdaq Capital Market, with the exception of the minimum bid price, and provides written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If the Company does not regain compliance within the allotted compliance period(s), Nasdaq will provide notice that the Company's common stock will be subject to delisting from the Nasdaq Capital Market. In that event, the Company may appeal such delisting determination to a hearings panel. The Company intends to monitor the closing bid price of its common stock and consider options to resolve its noncompliance with the minimum bid price requirement. 공시 • May 19
OncoSec Medical Incorporated has completed a Follow-on Equity Offering in the amount of $1.330923 million. OncoSec Medical Incorporated has completed a Follow-on Equity Offering in the amount of $1.330923 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 1,408,384
Price\Range: $0.945
Discount Per Security: $0.0709
Transaction Features: Registered Direct Offering 공시 • May 17
Oncosec Medical Incorporated Announces Type C Meeting with the US Food and Drug Administration to Discuss Proposed Neoadjuvant Melanoma Clinical Program OncoSec Medical Incorporated announced a Type C meeting held with the US Food and Drug Administration (FDA) on May 15, 2023. The purpose of the meeting was to discuss the trial design for a planned randomized, open-label Phase 2 clinical trial in patients with high-risk, resectable melanoma to evaluate the neoadjuvant treatment combination of the Company's tavokinogene telseplasmid, a plasmid encoding human interleukin 12 (IL-12), administered intratumorally by electroporation (TAVO(TM)-EP) with intravenous KEYTRUDA(R) (pembrolizumab), Merck's anti-PD-1 therapy. The meeting with the FDA represents an important next step on the Company's path to pursue clinical development of TAVO(TM)-EP in combination with anti-PD-1 therapy in the neoadjuvant melanoma setting. The Company discussed with the FDA the proposed design of a global randomized Phase 2 trial, which includes a primary endpoint of pathological complete response (pCR) rate and secondary endpoints including event-free survival (EFS) and pathological major response (pMR) rate. As discussed with the FDA, a single arm run-in stage is planned to confirm the appropriate neoadjuvant dosing schedule and allow the collection of mechanistic biomarker data to further evaluate the mechanism of action of TAVO(TM-EP as a trigger for anti-tumor immune effector functions. The Company's discussion with the FDA follows the release of interim data from an ongoing investigator-sponsored trial (IST) led by Dr. Ahmad Tarhini at the H. Lee Moffit Cancer Center & Research Institute evaluating TAVO(TM)- EP in combination with intravenous nivolumab, which showed encouraging clinical and pathological response rates. The Company appreciates the productive meeting with the FDA and the agency's feedback on the trial design and potential strategies for future registrational paths. Board Change • Jan 04
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Stephany Foster was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Price Target Changed • Apr 27
Price target decreased to US$5.00 Down from US$10.00, the current price target is provided by 1 analyst. New target price is 536% above last closing price of US$0.79. Stock is down 84% over the past year. The company is forecast to post a net loss per share of US$0.99 next year compared to a net loss per share of US$1.37 last year. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Jim DeMesa was the last independent director to join the board, commencing their role in 2011. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Price Target Changed • Mar 17
Price target decreased to US$5.00 Down from US$9.50, the current price target is provided by 1 analyst. New target price is 404% above last closing price of US$0.99. Stock is down 84% over the past year. The company is forecast to post a net loss per share of US$1.37 next year compared to a net loss per share of US$1.37 last year. Board Change • Dec 15
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 6 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Chairperson Margaret Dalesandro was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Executive Departure • Aug 18
Interim CEO & COO Brian Leuthner has left the company On the 13th of August, Brian Leuthner's tenure as Interim CEO & COO of the company ended after less than a year in the role. As of June 2021, Brian still personally held 34.39k shares (US$97k worth at the time). A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 1.92 years, which is considered inexperienced in the Simply Wall St Risk Model. Under Brian's leadership, the company delivered a total shareholder return of -20%. Breakeven Date Change • Aug 01
Forecast to breakeven in 2024 The 3 analysts covering OncoSec Medical expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$71.1m in 2024. Average annual earnings growth of 54% is required to achieve expected profit on schedule. Executive Departure • Jun 29
President, CEO & Director Daniel O'Connor has left the company On the 25th of June, Daniel O'Connor was replaced as CEO by Brian Leuthner after 3.6 years in the role. As of March 2021, Daniel still personally held 80.52k shares (US$384k worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 2.63 years. Under Daniel's leadership, the company delivered a total shareholder return of -86%. Price Target Changed • Mar 09
Price target raised to US$8.13 Up from US$7.33, the current price target is an average from 3 analysts. The new target price is 59% above the current share price of US$5.10. As of last close, the stock is up 223% over the past year. Is New 90 Day High Low • Jan 30
New 90-day high: US$7.71 The company is up 103% from its price of US$3.79 on 30 October 2020. The American market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 25% over the same period. Is New 90 Day High Low • Jan 12
New 90-day high: US$6.81 The company is up 75% from its price of US$3.90 on 13 October 2020. The American market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 14% over the same period. Is New 90 Day High Low • Dec 17
New 90-day high: US$6.65 The company is up 48% from its price of US$4.50 on 18 September 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 16% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Is New 90 Day High Low • Nov 07
New 90-day high: US$5.11 The company is up 27% from its price of US$4.01 on 07 August 2020. The American market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.